* Kronos Bio Inc KRON.OQ reported a quarterly adjusted
loss
of 57 cents per share for the quarter ended in September. The
mean expectation of five analysts for the quarter was for a loss
of 65 cents per share.
* Reported revenue was zero; analysts expected zero.
* Kronos Bio Inc's reported EPS for the quarter was a loss
of 57
cents.
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company.
* Kronos Bio Inc shares had fallen by 23.6% this quarter and
lost 81.2% so far this year.
* The company reported a quarterly loss of $32.26 million.
* Wall Street's median 12-month price target for Kronos Bio
Inc is
$15.00
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
This summary was machine generated from Refinitiv data November
9 at 05:24 a.m. All figures in US dollars unless otherwise
stated. QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2022 -0.65 -0.57 Beat
Jun. 30 2022 -0.69 -0.59 Beat
Mar. 31 2022 -0.66 -0.65 Beat
Dec. 31 2021 -1.10 -1.13 Missed